4D Molecular Therapeutics (FDMT) Return on Capital Employed (2021 - 2026)
4D Molecular Therapeutics (FDMT) reported Return on Capital Employed of 36.17% for Q1 2026, up 361.0% year-over-year from 7.85% in Q1 2025, and down 2.32% quarter-over-quarter from 35.35% in Q4 2025.
4D Molecular Therapeutics (FDMT) Return on Capital Employed (2021 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 6 years of Return on Capital Employed data on file, last reported at 36.17% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 36.17%, up 361.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 36.17% (up 361.0% YoY), and the FY2025 annual result was 30.71%, up 1391.0% from the prior year.
- Return on Capital Employed declined to 36.17% in Q1 2026 per FDMT's latest filing, from 35.35% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 21.67% in Q2 2024 and troughed at 55.96% in Q3 2025.
- A 5-year average of 36.42% and a median of 35.35% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed surged 2126 bps in 2024, then tumbled 2706 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 43.1% in 2022, then gained by 21 bps to 34.02% in 2023, then increased by 0 bps to 33.96% in 2024, then declined by 4 bps to 35.35% in 2025, then retreated by 2 bps to 36.17% in 2026.
- Business Quant data shows FDMT's Return on Capital Employed at 36.17% in Q1 2026, 35.35% in Q4 2025, and 55.96% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -36.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.17% |
| Dec 31, 2025 | -35.35% |
| Sep 30, 2025 | -55.96% |
| Jun 30, 2025 | -47.90% |
| Mar 31, 2025 | -39.78% |
| Dec 31, 2024 | -33.96% |
| Sep 30, 2024 | -28.90% |
| Jun 30, 2024 | -21.67% |
| Mar 31, 2024 | -25.81% |
| Dec 31, 2023 | -34.02% |
| Sep 30, 2023 | -30.96% |
| Jun 30, 2023 | -41.28% |
| Mar 31, 2023 | -47.07% |
| Dec 31, 2022 | -43.10% |
| Sep 30, 2022 | -38.16% |
| Jun 30, 2022 | -34.13% |
| Mar 31, 2022 | -24.89% |
| Dec 31, 2021 | -25.41% |
| Sep 30, 2021 | -28.34% |
| Jun 30, 2021 | -20.64% |